Mediwound announces exercise of over-allotment option

Yavne, israel, march 22, 2022 (globe newswire) -- mediwound ltd. (nasdaq: mdwd) (“mediwound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration, today announced that the underwriter of its recently completed public offering of ordinary shares, which closed on march 7, 2022, partially exercised their over-allotment option, having purchased an additional 623,082 ordinary shares. the closing of the partial exercise of the option occurred on march 22, 2022.
MDWD Ratings Summary
MDWD Quant Ranking